Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

Brief summary

This study will assess the use of an active drug in adult patients with moderate to severe chronic plaque psoriasis and compare an active drug to other commonly used biologics.

Observational study

Active, not recruiting
Chronic Plaque Psoriasis
2439 patients
Protocol ID:
Observational model:
Time perspective:


Eligibility criteria

Participant attributes:
Male and Female


18 Years and older.

Inclusion Criteria:

- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a
specialist and presence of moderate to severe psoriasis symptoms according to
physician's judgement at time of recruitment.

- Participant starting any approved treatment for psoriasis and physician's decision
must be reached prior to recruitment in the study.

- Participant willing to continue with study documentation after cessation of therapy.

Exclusion Criteria:

- Unwillingness or inability to comply with study requirements.

- Participation in an interventional clinical trial, concurrently or within the last 30
days. Participation in a post-market observational study (PMOS) or Registry is

All the cities where the clinical studies are located

Calgary - T3E 0B2
Edmonton - T5K 1X3
Edmonton - T6G 1C3
Vancouver - V5Z 3N9
St. John's - A1A 4Y3
St. John's - A1C 2H5
St. John's - A1E 1V4
Ajax - L1S 7K8
Barrie - L4M 7G1
Burlington - L7R 4H9
Hamilton - L8L 3C3
Hamilton - L8L 8E7
Hamilton - L8N 1Y2
Markham - L3P 1X2
Mississauga - L4W 0C2
Mississauga - L5H 1G9
Ottawa - K1H 7X3
Peterborough - K9J 5K2
Stoney Creek - L8G 1H1
Toronto - M2N 3A6
Waterloo - N2J 1C4
Whitby - L1N 8M7
Laval - H7N 6L2
Quebec City - G1W 4R4
Fredericton - E3B 1G9
Brandon - R7A 0L5
Winnipeg - R3C 0N2

More information about this study